Prospective evaluation of remifentanil‑propofol mixture for total intravenous anesthesia: A randomized controlled study

  • Authors:
    • Mefkur Bakan
    • Tarik Umutoglu
    • Ufuk Topuz
    • Emine Yilmaz Guler
    • Harun Uysal
    • Erdogan Ozturk
  • View Affiliations

  • Published online on: August 23, 2021     https://doi.org/10.3892/etm.2021.10632
  • Article Number: 1198
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Application of total intravenous anesthesia (TIVA) may be considered as unpractical when compared with inhalational anesthesia. Although it is mostly not recommended, mixing intravenous agents is popular in clinical practice. The aim of the present study was to investigate the suitability of using remifentanil‑propofol mixture (MIXTIVA) for TIVA. Adult patients with an American Society of Anesthesiologists grade of I‑II scheduled for elective thyroidectomy were randomly allocated to 3 groups (n=32 for each) to receive TIVA with remifentanil and propofol infusions separately (control group, Group I) or with MIXTIVA infusion that contained remifentanil/propofol at a proportion of 2/1,000 or 3/1,000 (remifentanil concentration, 20 or 30 µg/ml in 1% propofol in Group II or Group III, respectively). The extubation time (the primary outcome of the study), the orientation time and number of patients in whom intraoperative hypotension, hypertension or bradycardia episodes were encountered during anesthesia were comparable among the groups. The mean remifentanil infusion rate in Group III was significantly higher than that in the other groups. The mean propofol infusion rates and mean bispectral index (BIS) scores during anesthesia were comparable among groups. Hypotension accompanied with a high BIS was encountered in one patient in Group III. In conclusion, compared to the standard TIVA technique using separate drug infusions, MIXTIVA infusion used for thyroidectomies did not result in any statistically significant difference in recovery and clinical outcomes. This technique may be considered as a practical implementation for busy ambulatory centers performing general anesthesia. The present study was retrospectively registered at clinicaltrials.gov (trial registration no. NCT04394897).
View Figures
View References

Related Articles

Journal Cover

November-2021
Volume 22 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Bakan M, Umutoglu T, Topuz U, Guler EY, Uysal H and Ozturk E: Prospective evaluation of remifentanil‑propofol mixture for total intravenous anesthesia: A randomized controlled study. Exp Ther Med 22: 1198, 2021
APA
Bakan, M., Umutoglu, T., Topuz, U., Guler, E.Y., Uysal, H., & Ozturk, E. (2021). Prospective evaluation of remifentanil‑propofol mixture for total intravenous anesthesia: A randomized controlled study. Experimental and Therapeutic Medicine, 22, 1198. https://doi.org/10.3892/etm.2021.10632
MLA
Bakan, M., Umutoglu, T., Topuz, U., Guler, E. Y., Uysal, H., Ozturk, E."Prospective evaluation of remifentanil‑propofol mixture for total intravenous anesthesia: A randomized controlled study". Experimental and Therapeutic Medicine 22.5 (2021): 1198.
Chicago
Bakan, M., Umutoglu, T., Topuz, U., Guler, E. Y., Uysal, H., Ozturk, E."Prospective evaluation of remifentanil‑propofol mixture for total intravenous anesthesia: A randomized controlled study". Experimental and Therapeutic Medicine 22, no. 5 (2021): 1198. https://doi.org/10.3892/etm.2021.10632